8/1/2012 10:41:00 AM
LOS ANGELES--(BUSINESS WIRE)--On the heels of news that HIV/AIDS drug maker Gilead Sciences Inc.’s CEO John Martin has joined the “$50 million club” AIDS Healthcare Foundation (AHF), the nation’s largest HIV/AIDS nonprofit medical provider, criticized Martin and the company for providing him with such an ostentatious compensation package while the U.S. remains in the grips of an HIV/AIDS drug funding crisis. 1,800 Americans living with HIV/AIDS in nine states are currently on waiting lists to receive lifesaving medications through state AIDS Drug Assistance Programs (ADAPs), the safety net for low-income people in need of HIV/AIDS treatment. A key reason for the waiting lists is that high drug prices have made it so that fewer patients can be treated with the same amount of funding. Gilead manufactures the most commonly prescribed HIV/AIDS drugs, as well as some of the highest priced ones.
comments powered by